{"title":"Diagnostic yield and safety of Remebot robot-assisted stereotactic biopsy: a 496-case retrospective analysis of intracranial lesions.","authors":"Kaishan Wang, Feng Yan, Yaming Wang, Yongzhi Shan, Xiaotong Fan, Sichang Chen, Guoguang Zhao","doi":"10.3171/2026.2.JNS251592","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to evaluate the diagnostic yield, safety, and workflow advantages of the Remebot system in intracranial stereotactic biopsies.</p><p><strong>Methods: </strong>The authors retrospectively analyzed 496 consecutive patients who underwent Remebot-assisted stereotactic brain biopsy at a single institution between 2023 and 2024. Demographic, clinical, radiological, and pathological data were collected. Logistic regression analysis was used to identify predictors of nondiagnostic biopsy. Model performance was evaluated using McFadden's pseudo-R2 and receiver operating characteristic analysis. Perioperative complications were defined and graded according to the Common Terminology Criteria for Adverse Events (version 5.0).</p><p><strong>Results: </strong>The overall diagnostic yield was 85.9% (426/496), with high-grade glioma (32.7%) and hematological malignancies (20.4%) as the most common pathologies. Multivariate analysis identified deep lesion sampling (OR 0.51, 95% CI 0.27-0.94; p = 0.034) and younger age (OR 0.98, 95% CI 0.97-0.99; p = 0.006) as independent predictors of nondiagnostic results. Sex, lesion location (supratentorial vs infratentorial), and brainstem involvement were not associated with yield. The perioperative complication rate was 1.8% (9/496), with hemorrhage accounting for 77.8% of events. All complications occurred in male patients, predominantly in those with high-grade glioma. The Remebot system demonstrated notable workflow advantages, including integrated planning, automated registration, and compact modular design.</p><p><strong>Conclusions: </strong>Remebot-assisted stereotactic biopsy achieved a high diagnostic yield and low complication rate, comparable with that of international robotic platforms. Deep lesion sampling and younger age were found to increase the risk of nondiagnostic results, whereas sex and lesion location did not. The system's integrated workflow, automated registration, and cost-efficient accessibility broaden its clinical applicability and support its role as a reliable tool for minimally invasive neurosurgical diagnosis.</p>","PeriodicalId":16505,"journal":{"name":"Journal of neurosurgery","volume":" ","pages":"1-10"},"PeriodicalIF":3.8000,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3171/2026.2.JNS251592","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The aim of this study was to evaluate the diagnostic yield, safety, and workflow advantages of the Remebot system in intracranial stereotactic biopsies.
Methods: The authors retrospectively analyzed 496 consecutive patients who underwent Remebot-assisted stereotactic brain biopsy at a single institution between 2023 and 2024. Demographic, clinical, radiological, and pathological data were collected. Logistic regression analysis was used to identify predictors of nondiagnostic biopsy. Model performance was evaluated using McFadden's pseudo-R2 and receiver operating characteristic analysis. Perioperative complications were defined and graded according to the Common Terminology Criteria for Adverse Events (version 5.0).
Results: The overall diagnostic yield was 85.9% (426/496), with high-grade glioma (32.7%) and hematological malignancies (20.4%) as the most common pathologies. Multivariate analysis identified deep lesion sampling (OR 0.51, 95% CI 0.27-0.94; p = 0.034) and younger age (OR 0.98, 95% CI 0.97-0.99; p = 0.006) as independent predictors of nondiagnostic results. Sex, lesion location (supratentorial vs infratentorial), and brainstem involvement were not associated with yield. The perioperative complication rate was 1.8% (9/496), with hemorrhage accounting for 77.8% of events. All complications occurred in male patients, predominantly in those with high-grade glioma. The Remebot system demonstrated notable workflow advantages, including integrated planning, automated registration, and compact modular design.
Conclusions: Remebot-assisted stereotactic biopsy achieved a high diagnostic yield and low complication rate, comparable with that of international robotic platforms. Deep lesion sampling and younger age were found to increase the risk of nondiagnostic results, whereas sex and lesion location did not. The system's integrated workflow, automated registration, and cost-efficient accessibility broaden its clinical applicability and support its role as a reliable tool for minimally invasive neurosurgical diagnosis.
目的:本研究的目的是评估Remebot系统在颅内立体定向活检中的诊断率、安全性和工作流程优势。方法:作者回顾性分析了2023年至2024年在同一家机构连续接受rebot辅助立体定向脑活检的496例患者。收集了人口学、临床、放射学和病理资料。采用Logistic回归分析确定非诊断性活检的预测因素。采用McFadden's伪r2和接收机工作特性分析对模型性能进行评价。根据不良事件通用术语标准(5.0版)对围手术期并发症进行定义和分级。结果:总体诊断率为85.9%(426/496),其中高级别胶质瘤(32.7%)和血液系统恶性肿瘤(20.4%)是最常见的病理。多因素分析发现,深部病变取样(OR 0.51, 95% CI 0.27-0.94; p = 0.034)和年龄较小(OR 0.98, 95% CI 0.97-0.99; p = 0.006)是非诊断结果的独立预测因子。性别、病变部位(幕上vs幕下)和脑干受累程度与肿瘤产量无关。围手术期并发症发生率为1.8%(9/496),出血占77.8%。所有并发症均发生在男性患者中,主要发生在高级别胶质瘤患者中。Remebot系统展示了显著的工作流程优势,包括集成规划、自动注册和紧凑的模块化设计。结论:rebot辅助立体定向活检的诊断率高,并发症发生率低,与国际机器人平台相当。深病变取样和年轻的年龄被发现增加了非诊断结果的风险,而性别和病变位置没有。该系统的集成工作流程、自动注册和经济高效的可及性扩大了其临床适用性,并支持其作为微创神经外科诊断的可靠工具的作用。
期刊介绍:
The Journal of Neurosurgery, Journal of Neurosurgery: Spine, Journal of Neurosurgery: Pediatrics, and Neurosurgical Focus are devoted to the publication of original works relating primarily to neurosurgery, including studies in clinical neurophysiology, organic neurology, ophthalmology, radiology, pathology, and molecular biology. The Editors and Editorial Boards encourage submission of clinical and laboratory studies. Other manuscripts accepted for review include technical notes on instruments or equipment that are innovative or useful to clinicians and researchers in the field of neuroscience; papers describing unusual cases; manuscripts on historical persons or events related to neurosurgery; and in Neurosurgical Focus, occasional reviews. Letters to the Editor commenting on articles recently published in the Journal of Neurosurgery, Journal of Neurosurgery: Spine, and Journal of Neurosurgery: Pediatrics are welcome.